GN enters partnership to detect cognitive impairment in people with hearing loss
Hearing aid group GN is joining forces with US-based Sonde Health to develop vocal biomarkers to aid in the early detection and management of life-threatening diseases for millions of hearing loss patients.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Hearing aid group GN Store Nord, which is based in Denmark, has signed a multi-year strategic partnership with US-based company Sonde Health. Together, they will research and develop commercial vocal biomarkers for mild cognitive impairment, reports a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sonova wins Veterans Affairs market shares in December
For subscribers
Analyst: GN price drop is an obvious opportunity to buy
For subscribers
